Structural optimization of phthalazine derivatives for anti-HBV activities to improve oral bioavailability
Bioorganic & Medicinal Chemistry · 2025
DOI: 10.1016/j.bmc.2025.118259 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry, 2025. Verfasst von Yurong Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China…. Hauptthemen laut MEDLINE: Phthalazines, Antiviral Agents, Hepatitis B virus. Die Arbeit nennt 37 Literaturangaben. Gefördert von: Science and Technology Innovation Plan Of Shanghai Science and Technology Commission, National Natural Science Foundation of China, National Science and Technology Major Project.
Abstract (Originalsprache)
The hepatitis B virus (HBV) capsid protein forms a protective nucleocapsid essential for viral replication, establishing capsid assembly modulation as a promising therapeutic strategy. Based on previous mechanistic studies, we identified phthalazine derivatives as potent HBV capsid assembly modulators (CAMs), with Yhhu6517 exhibiting submicromolar antiviral activity in vitro. However, its clinical translation was hindered by poor oral pharmacokinetics (PK), due to rapid first-pass metabolism of oxidation-prone primary alcohol groups. Through metabolic stability-guided structure-activity relationship (SAR) studies involving systematic replacement of primary alcohols with non-primary alcohol-derived hydrophilic groups, we optimized the fragments to yield compound 2p. This optimized candidate 2p maintained a potent anti-HBV activity (IC50 = 0.016 μM in HepG2.2.15 cells) while demonstrating improved an oral bioavailability (F = 80.6 % in mice) and enhanced plasma exposure (AUC0-24h = 10.3 μg·h/mL). These findings confirm phthalazine-based anti-HBV agents, with compound 2p emerging as a candidate for the further development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China; School of Chinese Materia Medica, College of Pharmacy, Nanjing Unive…
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China; Immunological Disease Research Center, Shanghai Institute of Materia…
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China; University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beij…
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China. Electronic address: whchen@simm.ac.cn.
Förderung
- Science and Technology Innovation Plan Of Shanghai Science and Technology Commission
- National Natural Science Foundation of China
- National Science and Technology Major Project
Zitieren
APA
Yang, Y., Xiao, F., Zuo, J., Yang, L., Hu, Y., & Chen, W. (2025). Structural optimization of phthalazine derivatives for anti-HBV activities to improve oral bioavailability. Bioorganic & Medicinal Chemistry. https://doi.org/10.1016/j.bmc.2025.118259
Vancouver
Yang Y, Xiao F, Zuo J, Yang L, Hu Y, Chen W. Structural optimization of phthalazine derivatives for anti-HBV activities to improve oral bioavailability. Bioorganic & Medicinal Chemistry. 2025. doi:10.1016/j.bmc.2025.118259
BibTeX
@article{Yang2025,
author = {Yang, Yurong and Xiao, Fuling and Zuo, Jianping and Yang, Li and Hu, Youhong and Chen, Wuhong},
title = {Structural optimization of phthalazine derivatives for anti-HBV activities to improve oral bioavailability},
journal = {Bioorganic & Medicinal Chemistry},
year = {2025},
doi = {10.1016/j.bmc.2025.118259}
}
EUVIMED